Death and serious illness following influenza vaccination: a multidisciplinary investigation
- PMID: 19373848
- DOI: 10.1002/pds.1743
Death and serious illness following influenza vaccination: a multidisciplinary investigation
Abstract
Purpose: To evaluate a possible association between influenza vaccination and four deaths and four serious illnesses among 114 recent influenza vaccinees in a long-term care facility (LTCF) and two deaths from a nearby physician's office. All had received vaccine from the same lot (Lot A).
Methods: Field investigation including (1) a retrospective cohort study among LTCF residents who received Lot A or other influenza vaccine, (2) review of medical records of cases of death or serious illness, (3) active surveillance of deaths among 1500 community based Lot A vaccinees and (4) laboratory testing of vaccine from available Lot A vials.
Results: Medical record reviews showed no common clinical syndrome or cause of death. Laboratory testing of Lot A samples revealed no evidence of tampering and no differences compared to an unrelated lot. The risk of death or hospitalization was not significantly different between persons who received Lot A versus a comparison lot, Lot B (incidence rate ratio (IRR) = 0.9, 95%CI = 0.3-3.3).
Conclusions: There was no clinical or biological evidence pointing to inherent vaccine safety issues, nor was there a detectable increased risk of death or hospitalization among persons vaccinated with Lot A. Lot specific clustering of adverse events (AEs) may reflect medical events causally unrelated to vaccination. Rapid investigations of potential AEs are important to ensure vaccine safety and to maintain public and healthcare provider confidence in vaccines.
Similar articles
-
Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6. MMWR Morb Mortal Wkly Rep. 2009. PMID: 20010511
-
Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).J Clin Neuromuscul Dis. 2009 Sep;11(1):1-6. doi: 10.1097/CND.0b013e3181aaa968. J Clin Neuromuscul Dis. 2009. PMID: 19730016
-
Monitoring vaccine safety during an influenza pandemic.Yale J Biol Med. 2005 Oct;78(5):265-75. Yale J Biol Med. 2005. PMID: 17132333 Free PMC article. Review.
-
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):825-40. doi: 10.1002/pds.936. Pharmacoepidemiol Drug Saf. 2004. PMID: 15386719 Review.
-
Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons.J Infect Dis. 2004 Feb 1;189(3):450-8. doi: 10.1086/381165. Epub 2004 Jan 23. J Infect Dis. 2004. PMID: 14745702
Cited by
-
Reasons why nurses decline influenza vaccination: a qualitative study.BMC Nurs. 2017 Apr 28;16:20. doi: 10.1186/s12912-017-0215-5. eCollection 2017. BMC Nurs. 2017. PMID: 28465672 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical